PFE Reports earnings results
Summary
On February 3, 2026, Pfizer Inc. (NYSE: PFE) reported its financial results for the fourth quarter and full-year 2025 via an Exhibit 99 press release. The company achieved solid full-year 2025 results, including 6% operational revenue growth. Pfizer also reaffirmed its full-year 2026 financial guidance, previously provided on December 16, 2025. The company plans approximately 20 key pivotal study starts in 2026.
Why It Matters
This update is material as Pfizer reported solid full-year 2025 financial performance, including 6% operational revenue growth, and reaffirmed its 2026 financial guidance (via Ex. 99.1 press release). This provides investors with current performance metrics and future outlook, including plans for ~20 key pivotal study starts in 2026, signaling continued strategic investment and potential growth.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On February 3, 2026, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Tuesday, February 3, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive